With some Phase III clinical and real-world evidence showing superior effects on HbA1c reduction in type 2 diabetes and on weight loss for GLP-1/GIP analogs, such as Eli Lilly and Company’s tirzepatide, that favor the cAMP signaling pathway over β-arrestin recruitment, one Chinese developer is now hoping its similarly acting contender may benefit from the same differentiation.
Hangzhou-based Sciwind Biosciences Co., Ltd. has mentioned in published research papers that its long-acting, cAMP signaling biased GLP-1 analog...
